Revaprazan

Revaprazan (SB 641257) is reversible proton pump inhibitor. Revaprazan can inhibit gastric acid secretion and protect gastric mucosa. Revaprazan can inhibit IkappaB-alpha degradation as well as Akt inactivation, resulting in attenuation of H. pylori-induced COX-2 expression. Revaprazan can be used for the researches of infection and inflammmation, such as H. pylori-infected gastric inflammation and gastric ulcer[1][2].

Product Specifications

CAS Number

[199463-33-7]

Product Name Alternative

SB 641257

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Akt; Bacterial; COX; ERK; NF-κB; Proton Pump

Type

Reference compound

Related Pathways

Anti-infection; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/revaprazan.html

Solubility

10 mM in DMSO

Smiles

CC1=C(C)C(N2C(C)C3=C(C=CC=C3)CC2)=NC(NC4=CC=C(F)C=C4)=N1

Molecular Formula

C22H23FN4

Molecular Weight

362.44

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

References & Citations

[1]Lee JS, et al. Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling. J Clin Biochem Nutr. 2012 Sep;51 (2) :77-83. |[2]Kim HK, et al. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. J Gastroenterol Hepatol. 2010 Oct;25 (10) :1618-25.